国药一致
(000028)
| 流通市值：113.78亿 | | | 总市值：132.46亿 |
| 流通股本：4.78亿 | | | 总股本：5.57亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 17,823,409,770.31 | 73,415,858,423.13 | 55,124,490,690.34 | 36,796,598,397.42 |
| 营业收入 | 17,823,409,770.31 | 73,415,858,423.13 | 55,124,490,690.34 | 36,796,598,397.42 |
| 二、营业总成本 | 17,432,136,489.2 | 71,812,830,420.19 | 53,874,589,496.98 | 35,955,918,659.01 |
| 营业成本 | 16,048,355,305.97 | 65,575,391,355.23 | 49,344,552,244.9 | 32,864,811,704.71 |
| 税金及附加 | 46,449,417.86 | 186,308,472.54 | 138,886,408.14 | 93,371,344.03 |
| 销售费用 | 1,062,076,917.93 | 4,846,915,960.57 | 3,551,256,072.17 | 2,436,281,242.55 |
| 管理费用 | 239,432,364.39 | 1,001,267,356.4 | 703,403,641.94 | 466,644,282.14 |
| 研发费用 | 1,513,333.97 | 19,986,945.44 | 16,559,803.77 | 11,631,570.23 |
| 财务费用 | 34,309,149.08 | 182,960,330.01 | 119,931,326.06 | 83,178,515.35 |
| 其中:利息费用 | 33,327,843.81 | 194,497,657.99 | 131,316,934.07 | 91,098,772.3 |
| 其中:利息收入 | 5,687,522.18 | 46,952,873.74 | 37,578,395.86 | 27,390,711.07 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | 3,128,755.42 | 3,229,489.96 | - |
| 加:投资收益 | 57,982,973.89 | 217,607,416.92 | 165,074,116.96 | 136,126,440.88 |
| 资产处置收益 | -1,263,766.11 | 7,956,341.59 | 10,041,538.38 | 4,116,939.6 |
| 资产减值损失(新) | -1,351,906.57 | -290,177,026.92 | -4,041,733.23 | -4,694,534.61 |
| 信用减值损失(新) | -87,134,015.27 | -88,647,612.06 | -141,688,297.12 | -89,044,367.74 |
| 其他收益 | 17,080,301.93 | 59,932,952.93 | 50,961,278.62 | 39,312,260.63 |
| 四、营业利润 | 376,586,868.98 | 1,512,828,830.82 | 1,333,477,586.93 | 926,496,477.17 |
| 加:营业外收入 | 2,699,410.36 | 20,084,581.99 | 13,512,458.6 | 10,192,652.43 |
| 减:营业外支出 | 2,425,750.61 | 23,893,084.14 | 29,335,203.47 | 18,575,827.27 |
| 五、利润总额 | 376,860,528.73 | 1,509,020,328.67 | 1,317,654,842.06 | 918,113,302.33 |
| 减:所得税费用 | 71,699,564.96 | 380,671,650.91 | 298,257,458.01 | 205,519,499.88 |
| 六、净利润 | 305,160,963.77 | 1,128,348,677.76 | 1,019,397,384.05 | 712,593,802.45 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 305,160,963.77 | 1,128,348,677.76 | 1,019,397,384.05 | 712,593,802.45 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 287,462,500.32 | 1,135,926,834.84 | 957,118,469.53 | 665,907,312.44 |
| 少数股东损益 | 17,698,463.45 | -7,578,157.08 | 62,278,914.52 | 46,686,490.01 |
| 扣除非经常损益后的净利润 | 280,052,547.6 | 1,095,695,722.62 | 923,019,047.69 | 642,861,567.03 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.52 | 2.04 | 1.72 | 1.2 |
| (二)稀释每股收益 | 0.52 | 2.04 | 1.72 | 1.2 |
| 八、其他综合收益 | - | 1,970,509.18 | -36,254.21 | -36,254.21 |
| 归属于母公司股东的其他综合收益 | - | 1,172,484.56 | -36,254.21 | -36,254.21 |
| 九、综合收益总额 | 305,160,963.77 | 1,130,319,186.94 | 1,019,361,129.84 | 712,557,548.24 |
| 归属于母公司股东的综合收益总额 | 287,462,500.32 | 1,137,099,319.4 | 957,082,215.32 | 665,871,058.23 |
| 归属于少数股东的综合收益总额 | 17,698,463.45 | -6,780,132.46 | 62,278,914.52 | 46,686,490.01 |
| 公告日期 | 2026-04-30 | 2026-04-02 | 2025-10-31 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |